Xeureka Signs Contract with RealizeEdge Partners for the Discovery of Candidate Compounds for Targeted Protein Degraders

November 11, 2025

Xeureka Inc. (Minato-ku, Tokyo; President: Taisei Nagae; “Xeureka”) has signed a contract with RealizeEdge Partners Co., Ltd. (Chuo-ku, Tokyo; President: Yoshitsugu Shitaka; “RealizeEdge Partners”) for the discovery of candidate compounds for Targeted Protein Degraders (TPDs) directed against specific targets, as well as for Degrader-Antibody Conjugates (DACs)* – a novel modality that combines TPDs with antibodies. Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”), a research partner commissioned by RealizeEdge Partners, will also participate in the research under this agreement.

RealizeEdge Partners aims to create innovative pharmaceuticals through the establishment of drug discovery ventures and research support that leverage TPD and DAC technologies. As part of this effort, RealizeEdge Partners has commissioned Xeureka to support the discovery of candidate TPD compounds for new drug development.

Utilizing advanced computational drug discovery technologies, including predictive modeling of ternary complex structures mediated by TPDs and its proprietary Free Energy Perturbation (FEP)** software, Xeureka will contribute to the creation of groundbreaking new drug candidates. Under this agreement, Xeureka will retain the right to apply the computational techniques and expertise developed during the contract period for its own future research activities.

Axcelead DDP will leverage its strong capabilities in TPD drug discovery to conduct research from compound synthesis through in vitro evaluation.

Building on its proprietary large-scale supercomputing infrastructure and advanced computational drug discovery technologies, Xeureka provides drug discovery support services that utilize diverse computational approaches, including AI and large-scale molecular dynamics simulations. These services address a broad range of needs, from high-precision activity prediction to virtual screening of compound libraries on the scale of billions. In addition to its strengths in small-molecule drug discovery, Xeureka will further contribute to improving the efficiency and success rate of research in the emerging TPD modality.

 

* DAC (Degrader-Antibody Conjugate): A novel drug discovery modality that conjugates targeted protein degraders to antibodies, combining the high target selectivity of antibody therapeutics with the potent pharmacological activity of targeted protein degraders.
** Free Energy Perturbation (FEP): A statistical mechanics-based computational method used to calculate the change in free energy upon ligand–protein binding, enabling highly accurate activity predictions.

 

【About Xeureka Inc.】

  • Address: 3-2-2 Toranomon, Minato-ku, Tokyo, Japan
  • President: Taisei Nagae
  • Established: November 2021
  • Shareholders: MITSUI & CO., LTD. (100%)
  • Business: Providing AI drug discovery support services and high-performance computing environments (supercomputers) to pharmaceutical and biotech companies, as well as conducting joint research and development for the purpose of drug discovery.
  • URL: https://xeureka.co.jp/

 

【About RealizeEdge Partners Co., Ltd.】

  • Adress: 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan
  • President: Yoshitsugu Shitaka
  • Established: April 2025
  • Business: Startup studio in pharmaceutical R&D. Accelerating the creation of drug discovery startups transforming health and brightening lives by integrating scientific excellence with strategic and operational support.
  • URL: https://realizeedge.com/

 

【About Axcelead Drug Discovery Partners, Inc.】

  • Adress: 2-26-1 Muraokahigashi, Fujisawa, Kanagawa, Japan
  • President: Kengo Okada
  • Established:July 2017
  • Business: Providing advisory and research support services related to drug discovery projects
  • URL: https://axcelead-us.com/
BACK